X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (196) 196
oncology (158) 158
index medicus (138) 138
male (99) 99
lung neoplasms - pathology (94) 94
respiratory system (94) 94
female (92) 92
middle aged (86) 86
aged (84) 84
lung neoplasms - drug therapy (73) 73
lung cancer (64) 64
carcinoma, non-small-cell lung - drug therapy (63) 63
adult (62) 62
carcinoma, non-small-cell lung - pathology (57) 57
chemotherapy (56) 56
neoplasm staging (55) 55
prognosis (48) 48
lung cancer, non-small cell (42) 42
treatment outcome (42) 42
aged, 80 and over (40) 40
cancer (38) 38
survival (38) 38
antineoplastic combined chemotherapy protocols - therapeutic use (36) 36
lung neoplasms - diagnostic imaging (34) 34
care and treatment (33) 33
non-small cell lung cancer (33) 33
lung neoplasms - mortality (31) 31
carcinoma, non-small-cell lung - mortality (26) 26
survival rate (26) 26
diagnosis (25) 25
lung neoplasms - therapy (25) 25
surgery (25) 25
cisplatin - administration & dosage (24) 24
staging (24) 24
carcinoma, non-small-cell lung - diagnostic imaging (23) 23
nsclc (23) 23
darbepoetin alfa (22) 22
lymphatic metastasis (22) 22
research (22) 22
survival analysis (22) 22
antineoplastic agents - therapeutic use (21) 21
positron-emission-tomography (21) 21
prospective studies (21) 21
therapy (21) 21
anemia - drug therapy (20) 20
hematology, oncology and palliative medicine (20) 20
randomized controlled trials as topic (20) 20
tomography, x-ray computed (20) 20
antineoplastic agents - adverse effects (19) 19
carcinoma (19) 19
computed-tomography (19) 19
disease-free survival (19) 19
docetaxel (19) 19
double-blind (19) 19
erythropoietin - analogs & derivatives (19) 19
carcinoma, non-small-cell lung - therapy (18) 18
clinical trials (18) 18
fluorodeoxyglucose f18 (18) 18
lung neoplasms - surgery (18) 18
radiotherapy (18) 18
tumors (18) 18
anemia - chemically induced (17) 17
lung neoplasms - classification (17) 17
phase-iii trial (17) 17
quality of life (17) 17
trial (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
cisplatin (16) 16
double-blind method (16) 16
non-small-cell lung cancer (16) 16
positron-emission tomography (16) 16
quality-of-life (16) 16
radiopharmaceuticals (16) 16
cell lung-cancer (15) 15
induction chemotherapy (15) 15
pemetrexed (15) 15
phase-iii (15) 15
analysis (14) 14
cancer therapies (14) 14
carcinoma, non-small-cell lung - genetics (14) 14
carcinoma, non-small-cell lung - surgery (14) 14
immunotherapy (14) 14
lung neoplasms - diagnosis (14) 14
metastasis (14) 14
non-small cell lung carcinoma (14) 14
retrospective studies (14) 14
anemia (13) 13
bronchogenic-carcinoma (13) 13
combined modality therapy (13) 13
erythropoietin - therapeutic use (13) 13
health aspects (13) 13
neoplasm staging - methods (13) 13
neoplasms - drug therapy (13) 13
open-label (13) 13
tnm classification (13) 13
carcinoma, non-small-cell lung - secondary (12) 12
drug administration schedule (12) 12
fdg-pet (12) 12
guanine - analogs & derivatives (12) 12
lung neoplasms - genetics (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10030, pp. 1837 - 1846
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 822 - 835
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 38 - 47
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 452 - 463
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S125 - S127
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 13, pp. 1189 - 1197
Ceritinib is 20 times as potent as crizotinib at inhibiting anaplastic lymphoma kinase (ALK) in vitro. In patients, ceritinib produced antitumor responses in... 
TRIALS | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | MUTATION | ACQUIRED-RESISTANCE | CRIZOTINIB | CLINICAL RESISTANCE | KINASE INHIBITOR | STI-571 | EGFR | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2018, Volume 379, Issue 24, pp. 2342 - 2350
Journal Article
Lung Cancer, ISSN 0169-5002, 2007, Volume 57, Issue 2, pp. S12 - S17
Journal Article